Curis FY26 Q1 net loss widens to $24.2 million; revenue logs no revenue

Curis

Curis

CRIS

0.00
  • Curis posted a net loss of $24.2 million, or $1.25 per share, for quarter ended March 31, 2026, widening from a $10.6 million loss a year earlier.
  • Revenue was absent following sale of Erivedge royalties in fourth-quarter 2025, versus $2.4 million a year earlier.
  • Research and development expense fell to $6.4 million from $8.5 million, while general and administrative costs rose to $5.1 million from $4 million.
  • Other expense climbed to $12.7 million from $0.5 million on a change in fair value of warrant liability tied to January 2026 PIPE financing.
  • Cash and cash equivalents totaled $15 million; runway forecast extends into second-half 2027, including up to $20.2 million of potential Series B warrant proceeds tied to dosing fifth patient in TakeAim CLL study expected later in 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605121600PR_NEWS_USPR_____NE57821) on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.